-

Bristol-Myers Squibb to Hold Investor Day on April 2

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it will hold an Investor Day in New York City on Thursday, April 2, 2020. Giovanni Caforio, M.D., chairman and chief executive officer, and members of the leadership team will discuss the Company’s strategy, pipeline and business opportunities.

The event will be webcast simultaneously at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb company and Juno Therapeutics, a Bristol-Myers Squibb company.

Contacts

Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@celgene.com

Bristol-Myers Squibb Company

NYSE:BMY

Release Summary
Bristol-Myers Squibb to Hold Investor Day on April 2, 2020
Release Versions
$Cashtags

Contacts

Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@celgene.com

More News From Bristol-Myers Squibb Company

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma...

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026...
Back to Newsroom